Literature DB >> 33008926

A closer look at the mysterious HSD17B13.

X Charlie Dong1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33008926      PMCID: PMC7604724          DOI: 10.1194/jlr.C120001160

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


× No keyword cloud information.
  17 in total

1.  17beta-Hydroxysteroid dehydrogenase type 13 is a liver-specific lipid droplet-associated protein.

Authors:  Yuka Horiguchi; Makoto Araki; Kiyoto Motojima
Journal:  Biochem Biophys Res Commun       Date:  2008-03-24       Impact factor: 3.575

2.  Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease.

Authors:  Panu K Luukkonen; Taru Tukiainen; Anne Juuti; Henna Sammalkorpi; P A Nidhina Haridas; Onni Niemelä; Johanna Arola; Marju Orho-Melander; Antti Hakkarainen; Petri T Kovanen; Om Dwivedi; Leif Groop; Leanne Hodson; Amalia Gastaldelli; Tuulia Hyötyläinen; Matej Orešič; Hannele Yki-Järvinen
Journal:  JCI Insight       Date:  2020-03-12

3.  Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease.

Authors:  Wen Su; Yang Wang; Xiao Jia; Wenhan Wu; Linghai Li; Xiaodong Tian; Sha Li; Chunjiong Wang; Huamin Xu; Jiaqi Cao; Qifei Han; Shimeng Xu; Yong Chen; Yanfeng Zhong; Xiaoyan Zhang; Pingsheng Liu; Jan-Åke Gustafsson; Youfei Guan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-15       Impact factor: 11.205

4.  HSD17B13 and Chronic Liver Disease in Blacks and Hispanics.

Authors:  Julia Kozlitina; Stefan Stender; Helen H Hobbs; Jonathan C Cohen
Journal:  N Engl J Med       Date:  2018-11-08       Impact factor: 91.245

5.  HCV-Associated Liver Fibrosis and HSD17B13.

Authors:  Frédégonde About; Laurent Abel; Aurélie Cobat
Journal:  N Engl J Med       Date:  2018-11-08       Impact factor: 91.245

6.  High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant.

Authors:  Helene Gellert-Kristensen; Børge Grønne Nordestgaard; Anne Tybjaerg-Hansen; Stefan Stender
Journal:  Hepatology       Date:  2019-08-09       Impact factor: 17.425

7.  17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.

Authors:  Yanling Ma; Olga V Belyaeva; Philip M Brown; Koji Fujita; Katherine Valles; Suman Karki; Ynto S de Boer; Christopher Koh; Yanhua Chen; Xiaomeng Du; Samuel K Handelman; Vincent Chen; Elizabeth K Speliotes; Cara Nestlerode; Emmanuel Thomas; David E Kleiner; Joseph M Zmuda; Arun J Sanyal; Natalia Y Kedishvili; T Jake Liang; Yaron Rotman
Journal:  Hepatology       Date:  2019-03-05       Impact factor: 17.425

8.  A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease.

Authors:  Jie Yang; Eric Trépo; Pierre Nahon; Qian Cao; Christophe Moreno; Eric Letouzé; Sandrine Imbeaud; Quentin Bayard; Thierry Gustot; Jacques Deviere; Paulette Bioulac-Sage; Julien Calderaro; Nathalie Ganne-Carrié; Alexis Laurent; Jean Frédéric Blanc; Erwan Guyot; Angela Sutton; Marianne Ziol; Jessica Zucman-Rossi; Jean-Charles Nault
Journal:  Hepatology       Date:  2019-04-25       Impact factor: 17.425

9.  Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort.

Authors:  Quentin M Anstee; Rebecca Darlay; Simon Cockell; Marica Meroni; Olivier Govaere; Dina Tiniakos; Alastair D Burt; Pierre Bedossa; Jeremy Palmer; Yang-Lin Liu; Guruprasad P Aithal; Michael Allison; Hannele Yki-Järvinen; Michele Vacca; Jean-Francois Dufour; Pietro Invernizzi; Daniele Prati; Mattias Ekstedt; Stergios Kechagias; Sven Francque; Salvatore Petta; Elisabetta Bugianesi; Karine Clement; Vlad Ratziu; Jörn M Schattenberg; Luca Valenti; Christopher P Day; Heather J Cordell; Ann K Daly
Journal:  J Hepatol       Date:  2020-04-13       Impact factor: 25.083

Review 10.  Role of HSD17B13 in the liver physiology and pathophysiology.

Authors:  Wen Su; Zhuo Mao; Yiao Liu; Xiaoyan Zhang; Weizhen Zhang; Jan-Ake Gustafsson; Youfei Guan
Journal:  Mol Cell Endocrinol       Date:  2018-10-24       Impact factor: 4.102

View more
  2 in total

Review 1.  Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics.

Authors:  Simona Riccio; Rosa Melone; Caterina Vitulano; Pierfrancesco Guida; Ivan Maddaluno; Stefano Guarino; Pierluigi Marzuillo; Emanuele Miraglia Del Giudice; Anna Di Sessa
Journal:  World J Clin Pediatr       Date:  2022-03-23

Review 2.  Metabolic-associated fatty liver disease from childhood to adulthood: State of art and future directions.

Authors:  Francesca Lanzaro; Stefano Guarino; Elisabetta D'Addio; Alessandra Salvatori; Josè Alberto D'Anna; Pierluigi Marzuillo; Emanuele Miraglia Del Giudice; Anna Di Sessa
Journal:  World J Hepatol       Date:  2022-06-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.